A new study revealed safe MS treatment options during pregnancy, reassuring women to balance effective care with their plans ...

The European Commission (EC) has granted marketing authorisation under exceptional circumstances for InflaRx’s Gohibic ...

IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ...

Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarterPratteln, Switzerland, January 16, 2025 – ...

These launches belong to what Oelrich called “must-win battles” at Bayer as Xarelto loss of exclusivity reaches “full swing” ...

The European Medicines Agency (EMA) today revealed that, in 2024, it recommended 114 medicines for marketing authorization.

The new pan-European group of 73 regulators, companies and trial sites is backed by €66.8m in funding with a six-year goal.

ImmunityBio is at the forefront of developing innovative immunotherapies and cell therapies. The company has a vertically integrated approach, allowing it to oversee every step of development, from ...

Treating the growing problem of childhood obesity calls for exploring new approaches and treatments through well-designed ...

CEO Bill Sibold hailed 2024 as a "transformational year" for Madrigal Pharmaceuticals, but Wall Street isn't as enthusiastic ...

The drug is already approved in the US to treat ulcerative colitis, another form of inflammatory bowel disease ...

The UK’s health technology assessor, the National Institute for Health and Care Excellence (NICE) has issued positive Final Guidance that recommends Agamree (vamorolone) for use in the National Health ...